File name: Musculoskeletal & Joint disease Formulary BNF Section 10.
Original Date of issue: 30/03/2006
Last Reviewed: 08/03/2013
Version: 4
Page 4 of 9
Department: Pharmacy
Review Date:08/03/2015
Authorised: Drug and Therapeutics Committee
10.1.3
Drugs which suppress the rheumatic disease process For information on monitoring and side effects see Sharepoint/ medicines/ medicine management/ shared care guidelines For patient information leaflets see Sharepoint/ medicines/ medicine management/patient information leaflets. Formulary Product status C Abatacept Infusion (250mg)
C
Adalimumab Pre filled pen (40mg)
C
Azathioprine Tablets (25mg, 50mg Certolizumab Injection 200mg
C
C
Cyclophosphamide Tablets 50mg
C
Ciclosporin Capsules (25mg,50mg) Ciclosporin liquid 100mg/ml Etanercept 25mg and 50mg injections
C
C
Golimumab 50mg/0.5ml prefilled syringe / pen
C
Hydroxychloroquine Tablets (200mg) Infliximab Infusion (100mg)
C
Restriction Consultant Rheumatologist use only for the treatment of RA.Supported for use in-line with NICE TA195 (Aug 2010) Consultant Rheumatologist and Consultant Gastroenterologist use only. Use supported for use in-line with NICE TA199 (PsA) August 2010, NICE TA143 (AS) May 2008 Consultant Rheumatologist use only Consultant Rheumatologist use only. Use supported for use in-line with NICE TA186 Feb 2010. Restricted for use within agreed protocols under the supervision of appropriate specialists Restricted for use within agreed protocols under the supervision of appropriate specialists Consultant Rheumatologist use only. Use supported for use in-line with NICE TA199 (PsA) August 2010, NICE TA143 (AS) May 2008 Consultant Rheumatologist use only. Supported for use in-line with NICE TA233 (AS) August 2011, NICE TA220 (PsA), April 2011, NICE TA225 (RA) June 2011 Consultant Rheumatologist use only Consultant Rheumatologist and consultant gastroenterologist use only. Use supported for use in-line with NICE TA199 August 2010, NICE TA143 (AS)